IDH1 and neoplasm: However, metastases or recurrent disease appeared to occur less frequently in patients with IDH2 G2/3 tumours compared to IDH1 and IDHwt tumours (% metastases/recurrence, IDH1: 37%, IDH2: 13%, IDHwt: 23%, IDH1 vs IDH2: p = 0.04, Fig. 3B).